

## **MEDIA RELEASE**

11 July 2007

ACN 079 253 606

E [cvtopia@cvtopia.com.au](mailto:cvtopia@cvtopia.com.au)

[www.cytopia.com.au](http://www.cytopia.com.au)



Cytopia Limited      PO Box 6492  
Level 5      St Kilda Road Central  
Baker Heart Research      Melbourne Victoria 8008  
Institute Building      Australia  
Commercial Road  
Melbourne Victoria 3004  
Australia

### **Cytopia strengthens cancer clinical trial with new site**

Cytopia Limited (ASX: CYT) has gained approval from the relevant authorities to commence dosing patients with CYT997 in its oral Phase I clinical trial at the Mater Misericordiae Hospital in Townsville, Queensland. CYT997 is a novel vascular disrupting agent being developed by Cytopia to treat solid tumours. This new site augments the existing trial site at the Royal Brisbane and Women's Hospital and will allow the recruitment of patients from a wider population base.

The clinical investigator leading the Townsville site is Dr Bahram Forouzesh. Dr Forouzesh has considerable experience in oncology clinical trials and has previously held a Fellowship at the prestigious Cancer Therapy and Research Center at the University of Texas at San Antonio.

Dosing to patients at the Mater Hospital commenced on 2 July and subject to ongoing dose-escalation at the two sites, the company anticipates that the Phase I oral study will conclude in December 2007 as scheduled. No dose-limiting toxicities have yet been observed.

The oral trial, which employs accelerated dose-escalation, is designed to investigate the safety and tolerability of CYT997. It will be given by mouth to patients with a diverse range of solid tumours on a three-weekly cycle. Biomarker studies, including the use of sophisticated imaging techniques to measure the permeability (or leakiness) of the tumour blood vessels, will also be performed as a foundation for future Phase II programmes. Studies to investigate the oral absorption of CYT997 are also being undertaken.

With the Phase I intravenous trial close to achieving its primary objectives, the company also anticipates announcing its Phase II clinical development programme in August 2007.

#### **About Cytopia**

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer. Cytopia conducts its research and development via subsidiaries based in Melbourne and New York and specialises in discovering new molecules that can inhibit enzymes known as kinases, an exciting new class of drugs.

For more information please contact:

Mr Andrew Macdonald  
Chief Executive Officer  
T: +61 3 9522 6920  
E: [andrew.macdonald@cytopia.com.au](mailto:andrew.macdonald@cytopia.com.au)

Dr Gregg Smith  
Director, Drug Development & Operations  
T : +61 3 9522 6933  
E : [gregg.smith@cytopia.com.au](mailto:gregg.smith@cytopia.com.au)

or, visit our website at: [www.cytopia.com.au](http://www.cytopia.com.au)